Assessment cycle 2023 Q1 — page 9
Documents ratified in the 2023 Q1 assessment cycle, which ran from 1 January 2023 to 31 March 2023 and was ratified on 18 March 2023.
Documents ratified
-
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in prediabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low20 Feb 2024 -
Randomised crossover, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low02 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low07 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low14 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low01 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The…
Very low09 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low17 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low19 Jan 2024 -
Observational, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low07 Jul 2023 -
Single-arm open-label, phase 3 study of Exenatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low03 Dec 2023 -
Single-arm open-label, phase 3 study of Lixisenatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low16 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low27 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low24 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds…
Very low07 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low13 Aug 2023 -
Observational, phase 2 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low28 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds…
Very low12 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no…
Very low17 Jun 2023 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low16 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low22 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low21 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low11 Aug 2023 -
Randomised crossover, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low16 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low05 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low19 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low02 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low15 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low02 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low10 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low01 May 2023 -
Single-arm open-label, phase 2 study of Liraglutide in mash over open-label extension of the parent trial. The Institute holds no reported primary result for this record…
Very low04 Jan 2024 -
Randomised crossover, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low18 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Aug 2023
page 9 of 13